Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2016

01-10-2016 | Original Article

Prevalence and associates of psychological distress in haematological cancer survivors

Authors: Alix E. Hall, Rob W. Sanson-Fisher, Mariko L. Carey, Chris Paul, Anna Williamson, Ken Bradstock, H. Sharon Campbell

Published in: Supportive Care in Cancer | Issue 10/2016

Login to get access

Abstract

Purpose

To explore outcomes of psychological distress, including anxiety, depression and stress, amongst adult haematological cancer survivors, with a specific focus on potential differences between rural and urban survivors.

Methods

One thousand four hundred fourteen urban and rural survivors were recruited from five Australian population-based cancer registries and completed a self-report pen-and-paper survey on their well-being, including the Depression Anxiety and Stress Scale 21-item version.

Results

A quarter of survivors were identified as reporting above normal levels of anxiety and depression, respectively, and almost one fifth (17 %) reported above normal levels of stress. There were no statistically significant differences in the percentage of rural and urban survivors reporting above normal levels of anxiety, depression, or stress. Survivors who had experienced financial burden due to their cancer or were of middle age had higher odds of reporting multiple domains of psychological distress, compared to their counterparts.

Conclusions

Haematological cancer survivors diagnosed during middle age or who experience increased financial burden as a result of their diagnosis may require additional support and care with regards to psychological distress.
Literature
1.
Carlson LE, Angen M, Cullum J, Goodey E, Koopmans J, Lamont L, Bultz BD (2004) High levels of untreated distress and fatigue in cancer patients. Br J Cancer 90(12):2297–2304PubMedPubMedCentral
2.
Linden W, Vodermaier A, MacKenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141(2):343–351CrossRefPubMed
3.
Allart P, Soubeyran P, Cousson-Gélie F (2013) Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature. Psycho-Oncology 22(2):241–249PubMed
4.
Ell K, Sanchez K, Vourlekis B, Lee PJ, Dwight-Johnson M, Lagomasino I, Russell C (2005) Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 23(13):3052–3060CrossRefPubMedPubMedCentral
5.
DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160(14):2101–2107CrossRefPubMed
6.
Molassiotis A, Wilson B, Blair S, Howe T, Cavet J (2011) Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psycho-Oncology 20(1):88–97CrossRefPubMed
7.
Montgomery C, Pocock M, Titley K, Lloyd K (2003) Predicting psychological distress in patients with leukaemia and lymphoma. J Psychosom Res 54(4):289–292CrossRefPubMed
8.
Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ (2009) Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 15:12–20CrossRefPubMed
9.
Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, Kaasa S (2004) A prospective study of health-related quality of life, fatigue, anxiety and depression 3–5 years after stem cell transplantation. Bone Marrow Transplant 34:257–266CrossRefPubMed
10.
Tecchio C, Bonetto C, Bertani M, Cristofalo D, Lasalvia A, Nichele I, Bonani A, Andreini A, Benedetti F, Ruggeri M, Pizzolo G (2013) Predictors of anxiety and depression in hematopoietic stem cell transplant patients during protective isolation. Psycho-Oncology 22:1790–1797CrossRefPubMed
11.
Clinton-McHarg T, Carey M, Sanson-Fisher R, Tzelepis F, Bryant J, Williamson A (2014) Anxiety and depression among haematological cancer patients attending treatment centres: prevalence and predictors. J Affect Disord 165:176–181CrossRefPubMed
12.
Priscilla D, Hamidin A, Azhar MZ, Noorjan KON, Salmiah MS, Bahariah K (2011) Assessment of depression and anxiety in haematological cancer patients and their relationship with quality of life. East Asian Arch Psychiatr 21:108–114
13.
Santos FR, Kozasa EH, Maria de Lourdes LF, Colleoni GW, Leite JR (2006) Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. J Psychosom Res 60(5):505–511CrossRefPubMed
14.
McCorkle R, Cooke E (2013) Psychosocial aspects of hematologic disorders. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastais J (eds) Hematology: basic principles and practice, 6th edn. Elsevier Inc., Philadelphia
15.
National Institute for Clinical Excellence (2003) Guidance on cancer services- improving outcomes in haematological cancers: the manual. NICE, London, UK
16.
Butow PN, Phillips F, Schweder J, White K, Underhill C, Goldstein D (2012) Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer 20(1):1–22CrossRefPubMed
17.
Weaver KE, Geiger AM, Lu L, Case LD (2013) Rural-urban disparities in health status among US cancer survivors. Cancer 119(5):1050–1057CrossRefPubMed
18.
Boyes AW, Girgis A, D’Este C, Zucca AC (2011) Flourishing or floundering? Prevalence and correlates of anxiety and depression among a population-based sample of adult cancer survivors 6 months after diagnosis. J Affect Disord 135(1):184–192CrossRefPubMed
19.
Schootman M, Homan S, Weaver KE, Jeffe DB, Yun SY (2013) The health and welfare of rural and urban cancer survivors in Missouri. Prev Chronic Dis 10:130052CrossRef
20.
Paul CL, Hall AE, Carey ML, Cameron EC, Clinton‐McHarg T (2013) Access to care and impacts of cancer on daily life: do they differ for metropolitan versus regional hematological cancer survivors? J Rural Health 29(s1):s43–50CrossRefPubMed
21.
Dauch S, Dolbeault S, Reich M (2013) Depression in cancer patients. Eur J Cancer Suppl 2:205–215CrossRef
22.
Traeger L, Greer JA, Fernandez-Robles C, Temel JS, Pirl WF (2012) Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 30(11):1197–1205CrossRefPubMed
23.
24.
Twombly R (2004) What’s in a name: who is a cancer survivor? J Nat Cancer Inst 96(19):1414–1415CrossRefPubMed
25.
Australian Bureau of Statistics (2013) Australian Statistical Geography Standard (ASGS): volume 5—remoteness structure. ABS Catalogue No. 1270.0.55.005. ABS, Canberra
26.
Hall AE, Sanson-Fisher RW, Lynagh MC, Threlfall T, D’Este CA (2013) Format and readability of an enhanced invitation letter did not affect participation rates in a cancer registry-based study: a randomized controlled trial. J Clin Epidemiol 66(1):85–94CrossRefPubMed
27.
Hall A, D’Este C, Tzelepis F, Sanson-Fisher R, Lynagh M (2014) The Survivor Unmet Needs Survey (SUNS) for haematological cancer survivors: a cross-sectional study assessing the relevance and psychometric properties. BMC Health Serv Res 14(1):211–223CrossRefPubMedPubMedCentral
28.
Lynagh M, Clinton-McHarg T, Hall A, Sanson-Fisher R, Stevenson W, Tiley C, Bisquera A (2015) Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies. Exp Hematol Oncol 4(15)
29.
Lovibond SH, Lovibond PF (1995) Manual for the Depression Anxiety Stress Scales, 2nd edn. Psychology Foundation Monograph, Sydney
30.
Brown TA, Chorpita BF, Korotitsch W, Barlow DH (1997) Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther 35(1):79–89CrossRefPubMed
31.
Gloster AT, Rhoades HM, Novy D, Klotsche J, Senior A, Kunik M, Stanley MA (2008) Psychometric properties of the Depression Anxiety and Stress Scale-21 in older primary care patients. J Affect Disord 110(3):248–259CrossRefPubMedPubMedCentral
32.
33.
National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology: distress management version 2.2103. NCCN,
34.
Walker J, Sawhney A, Hansen CH, Ahmed S, Martin S, Symeonides S, Murray G, Sharpe M (2014) Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychol Med 44:897–907CrossRefPubMed
35.
Goldstein D, Underhill C (2007) Regional cancer services in Australia: some evidence of improvement but a long way to go. Cancer Forum 2(31)
36.
McGrath P (2000) It’s horrendous-but really, what can you do? Preliminary findings on financial impact of relocation for specialist treatment. Aust Health Rev 23(3):94–103CrossRefPubMed
37.
McGrath P, Seguerra J (2000) The patient transit assistance scheme: a consumer’s perspective. Aust J Rural Health 8(4):232–238CrossRefPubMed
38.
Bleyer A (2005) The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 35(5):182–217CrossRefPubMed
39.
McAdams DP, Olson BD (2010) Personality developing continuity and change over the life course. Annu Rev Psychol 61:517–542CrossRefPubMed
40.
Hammond CT, Beckjord EB, Arora NK, Bellizzi KM, Jeffery DD, Aziz NM (2008) Non-Hodgkin’s lymphoma survivors’ fertility and sexual function-related information needs. Fertil Steril 90(4):1256–1258CrossRefPubMed
41.
Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, Baker F (2007) The rationale, design, and implementation of the American Cancer Society’s studies of cancer survivors. Cancer 109(1):1–12CrossRefPubMed
42.
Watson N, Wooden M (2009) Identifying factors affecting longitudinal survey response. In: Lynn P (ed) Methodology of longitudinal surveys. John Wiley & Sons Ltd, Chichester
43.
Australian Bureau of Statistics (2015) 3218.0 regional population growth, Australia population estimates by remoteness area, 2004 to 2014. ABS, Canberra
Metadata
Title
Prevalence and associates of psychological distress in haematological cancer survivors
Authors
Alix E. Hall
Rob W. Sanson-Fisher
Mariko L. Carey
Chris Paul
Anna Williamson
Ken Bradstock
H. Sharon Campbell
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3282-3

Other articles of this Issue 10/2016

Supportive Care in Cancer 10/2016 Go to the issue

Original Article

Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy

Original Article

Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment

Original Article

Sleep disorders in breast cancer survivors

Original Article

Determinants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT

Original Article

Quality of life-related outcomes from a patient-tailored integrative medicine program: experience of Russian-speaking patients with cancer in Israel

Original Article

The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits